ATLANTA, Sept. 16, 2026 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital, engineering, and scientific solutions for health and defense missions, today announced that it has been awarded a task order to continue providing high-quality information technology services for the National Heart, Lung, and Blood Institute (“NHLBI”).

DLH has performed on this mission since 2018. The task order, valued at up to $43.7 million, includes a base period and multiple options aggregating to a two-and-a-half-year period of performance. The Company will provide services in support of approximately 2,000 NHLBI scientific and administrative employees and contractors.

Under this task order, DLH will build on its existing implementation of artificial intelligence for IT operations (“AIOps”) and automation to improve service efficiency, system reliability, data integrity, cybersecurity, and compliance. Services include:

  • Scientific technology support
  • Application support services
  • Tiered service desk
  • Configuration management
  • Infrastructure operations across on-premises and cloud environments
  • Cybersecurity operations

“By combining scientific expertise with cloud, cybersecurity, application support, and AIOps capabilities, DLH remains a trusted partner for customers seeking mission-critical federal health technology services,” said DLH President & CEO Kathryn JohnBull. “We are pleased that this award extends our longstanding relationship with NHLBI. We expect to continue driving technology modernization, improved operating efficiency through automation, and reduced risk in support of the organization’s critical biomedical research mission.”

About DLH

DLH (NASDAQ: DLHC) enhances technology, public health, and cyber security readiness missions through science, technology, cyber, and engineering solutions and services. Our experts solve some of the most complex and critical missions faced by federal customers, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With a world-class workforce dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to innovative solutions to improve the lives of millions. For more information, visit www.DLHcorp.com.

Contact Information:

Investor Relations

investorrelations@dlhcorp.com

Media

communications@dlhcorp.com

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward-looking statements that involve risks and uncertainties which could cause actual events or DLH’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements in this release include, among others, statements regarding expected contract performance, future task order value, and anticipated operational benefits. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements due to a variety of factors, including: the failure to achieve the anticipated benefits of any future acquisition (including anticipated future financial operating performance and results); the inability to retain employees and customers; contract awards in connection with re-competes for present business and/or competition for new business; our ability to manage our debt obligations; compliance with bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid and award protests, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; significant delays or reductions in appropriations for our programs and broader changes in U.S. government funding and spending patterns; legislation that amends or changes discretionary spending levels or budget priorities; legal, regulatory, and political changes from the federal government that could result in economic uncertainty; the impact of inflation and higher interest rates; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2025, as well as interim quarterly filings thereafter. The forward-looking statements contained herein are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and business. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements.

SINGAPORE, Sept. 16, 2026 (GLOBE NEWSWIRE) — Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced the pricing of its firm commitment public offering of an aggregate 4,322,489 shares of its Class A Ordinary Shares (“the Offering”), all of which are being offered by CUPR at a public offering price of $1.15 per share (“the Offering Price”), for a total of approximately $4.97 million of gross proceeds to the Company, before deducting underwriting discounts and offering expenses.

The Company has granted the underwriter a 45-day option to purchase up to an additional 648,373 shares of its Class A Ordinary Shares at the Offering Price, representing 15% of the Class A Ordinary Shares sold in the Offering (“the Over-allotment”). Assuming that the Over-allotment is exercised, the Company is expected to receive gross proceeds amounting to approximately $5.72 million, before deducting underwriting discounts and commissions and estimated offering expenses.

The Offering is expected to close on or about September 17, 2026, subject to the satisfaction of customary closing conditions.

R. F. Lafferty & Co., Inc. (“R. F. Lafferty”), acted as the sole book-running manager for the Offering. Loeb & Loeb LLP, Lee & Lee, Harney Westwood & Riegels Singapore LLP are acting as U.S., Singapore and Cayman Islands legal counsels to the Company, respectively, and Ellenoff Grossman & Schole LLP is acting as U.S. legal counsel to R. F. Lafferty for the Offering.

The Offering is being conducted pursuant to the Company’s Registration Statement on Form F-1 (File No: 333-297299) previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission (“SEC”) on September 15, 2026. The Offering is being made only by means of a prospectus. Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. Copies of the final prospectus related to the Offering may be obtained, when available, from R. F. Lafferty & Co., Inc., 40 Wall Street, Suite 3602, New York, NY 10005; (212) 293-9090, or by email at offerings@rflafferty.com. In addition, a copy of the final prospectus, when available, relating to the Offering may be obtained via the SEC’s website at www.sec.gov.

This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Cuprina Holdings (Cayman) Limited

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the infertility, medical waste recycling, and health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit https:// www.cuprina.com.

FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected completion, timing and gross proceeds of the offering. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Cuprina Holdings (Cayman) Limited Investor Contact

Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg

Company plans to change its name to FG Communities Holdings, Inc.

Charlotte, NC, Sept. 16, 2026 (GLOBE NEWSWIRE) — FG Nexus (Nasdaq: FGNX, FGNXP) (the “Company”) today announced that its Board of Directors has approved a strategy to acquire affordable housing communities and make a $10 million investment in FG Communities, Inc. (“FG Communities”), representing approximately 10% of FG Communities outstanding common stock. FG Communities, a privately held self-administered and self-managed real estate company focused on preserving and improving affordable housing through the acquisition and operation of manufactured housing communities, has a growing portfolio of 96 communities with over 4,000 home sites either owned or pending acquisition. FG Communities will remain a separate, independently operated company following the Company’s investment. This strategy is the next step in the Company’s previously announced transition into a real estate operating company focused primarily on the acquisition and management of land-lease affordable housing communities.

Direct and Indirect Investments in Affordable Housing

The Company’s strategy has two components: direct acquisitions of real property by the Company itself, and an indirect investment through its $10 million investment in FG Communities, which will continue to operate independently under its own management. The Company plans to pursue a strategy of acquiring real estate with land-lease affordable housing communities. The Company expects to fund direct property acquisitions through a combination of cash on hand, debt financing and proceeds from issuances of its common stock. The structure and financing of each acquisition will depend on the characteristics of the property, prevailing market conditions and the Company’s capital-allocation priorities.

Certain officers and directors of the Company, including Kyle Cerminara, also hold significant equity positions in, and serve as officers and directors of, FG Communities. Because certain directors and officers of the Company are affiliated with FG Communities, the Company’s proposed investment was evaluated and approved by the Board of Directors following a review and recommendation from its Special Committee, consisting solely of independent directors, and an independent financial advisor. Kyle Cerminara, Chairman and Chief Executive Officer of the Company, also serves as President and Chairman of FG Communities.

Kyle Cerminara, Chairman and Chief Executive Officer of the Company, stated:

“The planned real estate acquisition strategy marks an important step in our transformation into a leading owner and operator of land-lease affordable housing communities. The Company’s mission will be to preserve and improve affordable housing in the United States. We estimate that the total addressable market for affordable housing communities in the United States exceeds $500 billion. It is a large and highly fragmented market that we intend to participate in meaningfully over the coming decades. We have identified a strong pipeline of potential acquisition opportunities. Leveraging FG Nexus’s balance sheet and access to capital should allow us to aggressively acquire land-lease affordable housing communities and build a substantial portfolio of income-producing real estate.”Mr. Cerminara continued:

“FG Communities has built a scalable operating platform for the acquisition and management of land-lease affordable housing communities. We believe our investment in FG Communities provides an immediate and opportune investment opportunity in land-lease affordable housing communities. We also anticipate that our investment in FG Communities will benefit the Company in growing and optimizing its planned affordable housing portfolio.”

Corporate Name and Ticker Symbol Changes

In connection with its strategic transformation, the Company plans to change its corporate name to FG Communities Holdings, Inc. The Company’s new name reflects its strategic focus on affordable housing and does not reflect majority ownership or control of FG Communities, Inc., which is a separate, privately held company.

The Company also plans to change the Nasdaq ticker symbol for its common stock from FGNX to FGC and the ticker symbol for its 8.00% Cumulative Preferred Stock, Series A, from FGNXP to FGCPP.

The name and ticker-symbol changes are expected to become effective soon, subject to completion of applicable corporate filings and confirmation by Nasdaq. Until the effective date, the Company’s common and preferred stock will continue to trade under FGNX and FGNXP, respectively. The Company will announce the effectiveness of the changes to the Company’s name and ticker symbols.

No action is expected to be required from existing stockholders in connection with the name or ticker-symbol changes.

About FG Nexus

FG Nexus (Nasdaq: FGNX, FGNXP) is a merchant bank and real estate focused operating company.

The FGNX® logo is a registered trademark.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are entitled to the protection of the safe-harbor provisions of those laws.

Forward-looking statements include statements concerning the closing and anticipated benefits of the Company’s proposed investment in FG Communities; the Company’s strategy to make direct investments in affordable housing communities; the acquisition, ownership, operation and financing of manufactured housing communities; the use of cash, debt financing and proceeds from common-stock issuances to fund acquisitions; the proposed corporate name and ticker-symbol changes; future share repurchases; the Company’s acquisition pipeline and growth strategy; and the anticipated size and long-term characteristics of the manufactured housing market.

These statements are based on management’s current expectations, assumptions, estimates and projections and involve risks and uncertainties, many of which are beyond the Company’s control. Actual results could differ materially from those expressed or implied by these statements.

Relevant risks include, among others, the Company’s ability to complete the proposed investment on anticipated terms; obtain required corporate, regulatory and Nasdaq approvals; successfully identify, finance, complete and integrate property acquisitions; obtain debt or equity financing on acceptable terms; manage leverage and potential dilution from equity issuances; realize anticipated operating and financial benefits; maintain adequate liquidity; and appropriately manage potential conflicts of interest arising from related-party transactions.

Additional risks are described in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statement except as required by law.

Contacts

Media Contact
media@fgnexus.io

Investor Contact
invest@fgnexus.io

The CRML Mines to Metals begins marking a significant move in the rare earth industry to full supply chain control

NEW YORK, Sept. 16, 2026 (GLOBE NEWSWIRE) — Critical Metals Corp. (Nasdaq: CRML) (“Critical Metals” or the “Company”), a leading critical minerals mining company, today announced further details of its mine-to-metals strategy aimed at maximizing supply-chain security and the potential value derived from the Tanbreez Rare Earth Project in Greenland.

The proposed CRML Romanian joint venture refinery, which is expected to receive 50% of all concentrate production under the existing term sheet, incorporates three major process innovations that are projected to enhance project economics:

  • Multistage mixed-acid reactor additions designed to prevent silica gel formation, a challenge encountered in other eudialyte processing routes. (Patent pending)
  • Complete silica recovery through off-gas recovery, designed to produce 99.99% SiO2 powder, reduce tailings to less than 1.5% of feed material and recycle acid, potentially reducing fresh acid consumption by approximately 85% while generating an additional high-value product stream;
  • Vacuum freeze-drying (lyophilisation) of all 19 chloride salts, designed to produce anhydrous, ultra-low-moisture powders that may command price premiums over conventionally dried material.

The proposed CRML Romania Process Refinery is being designed with capacity to process up to 100,000 tons per year of eudialyte concentrate feed and based on current modelling, produce approximately 27,943 tons per year of rare earth and critical metal products in the form of chloride salts and other ultra-pure products.

Projected by-products include 25,670 tons per year of high purity SiO2 powder.

Based on current modelling and assumed market pricing, projected annual revenue from the silica by-product could reach approximately US$600 million.

The current preliminary CAPEX estimate is US$1,85 billion (+/-25% Class 4 estimate).

Current modelling projects annual revenue of approximately US$2,2 billion before operating costs, taxes and capital recovery.

Current modelling indicates an NPV10 of approximately US$4.5 billion, an IRR of approximately 55% and a projected payback period of approximately two years.

The silicate recovery system is projected to contribute approximately US$400-600 million per year in combined value from SiO2 revenue and avoided acid costs, potentially transforming a conventional waste stream into a significant revenue contributor. Based on current modelling and pricing assumptions key value drivers include SiO2, NbCl5, DyCl3, TaCl5 and Hafnium products.

The proposed CRML Romania Process Refinery uses a multistage, mixed-acid leach process operating at elevated temperatures, followed by cascading recovery steps designed to produce high-purity rare earth salts, metals and critical metal salts for advanced industrial, aerospace, technology and defense applications.

A key feature of the proposed process is the recovery of materials that would traditionally report to tailings, including silica and potentially alumina, iron and copper. Current process modelling targets a tailings stream of approximately 1% of feed tonnage, supporting the Company’s objective of developing a lower-waste processing route.

The proposed process route then through a multistage ion-exchange system, with multiple recovery stages for individual elements, designed to achieve high-purity products in the 99.9-99.99% range, subject to further test work and process validation.

The proposed production route for high-purity hafnium products utilizes established processing technologies. Based on current modelling, CRML Romania could produce approximately 50-70 tons per annum of high-purity hafnium metal during its first five years, together with approximately 20-30 tons per annum of high-purity hafnium chloride. These projections remain subject to further engineering, metallurgical test work, market conditions, permitting and final investment decisions.

The proposed CRML Romania Process Refinery is currently estimated to require up to 150 MW of energy input from gas and/or electricity. Current design assumptions contemplate approximately 60-70% of energy demand being supplied by gas-fired kilns and boilers and approximately 30-40% by third-party or state electricity suppliers.

The proposed CRML Romania Process Refinery is being designed as a low-wastewater and low-tailings operation. Current modelling targets refinery tailings of approximately 1% of input tonnage and limited wastewater discharge, subject to further engineering, environmental studies and permitting. Potential treatment pathways include third-party or approved government facilities in Romania.

Multiple acids and ammonia are expected be generated onsite, with certain high-purity feed materials to be sourced from suppliers in Europe or the United States. The proposed supply strategy is intended to support a secure Western supply chain.

Locating the proposed refinery in Romania, an EU and NATO member state, is intended to support a secure Western supply chain. Current planning contemplates multiple shipping and rail routes for the movement of Tanbreez concentrate from Greenland to the proposed refinery location in Romania.

If developed as currently contemplated, CRML Romania has the potential to become a significant Western supplier of rare earths and critical metals.

The following tables present projected refinery product values based on current modelling, assumed market prices and estimated market demand. These projections are preliminary and remain subject to further engineering, test work, market conditions and completion of feasibility studies.

Current modelling assumes a Tanbreez eudialyte concentrate transfer or sales value of approximately US$4,000 per ton. The refinery model indicates potential revenue of up to approximately US$24,000 per ton of concentrate processed, before operating costs currently estimated at approximately US$3,500-4,000 per ton and before capital recovery, taxes and other costs.

For the base-case economic analysis, current modelling assumes revenue of approximately US$13,000 per ton of eudialyte concentrate processed, using lower historical market pricing assumptions, resulting in approximately US$9,000 per ton before tax and capital recovery based on the current model.

The higher-price case uses 2025-2026 market pricing assumptions of approximately US$24,000 per ton of concentrate processed, resulting in approximately US$20,000 per ton before tax and capital recovery based on the current model. These figures are preliminary modelling assumptions and are subject to commodity prices, recoveries, operating costs, capital costs and further feasibility work.

Tony Sage, Executive Chairman and CEO of Critical Metals Corp., commented:

“This represents a significant evolution in the Tanbreez value proposition and reinforces our commitment to a true mine-to-metals strategy. By combining Tanbreez’s exceptional eudialyte resource with advanced processing in Romania, we have the potential to capture substantially more value from every ton of material while producing the high-purity rare earths and critical metals that Western markets increasingly require.

Importantly, our proposed process is designed to recover valuable by-products such as high-purity silica rather than treating them as waste, potentially improving both the economic and environmental profile of the operation. We believe this integrated approach has the potential to establish Critical Metals Corp. as an important non-Chinese supplier of critical materials to the European and U.S. markets, with Tanbreez providing the resource foundation and the proposed Romanian refinery delivering the downstream value.”

Critical Metals Corp

Fig. 1. Projected Revenue Table and Rare Earth and Critical Metal Production, Excluding By-products

Critical Metals Corp

Fig. 2. Rare Earth Element Distribution

Critical Metals Corp

Fig. 3. Rare Earth Distribution in Tanbreez Concentrate

Critical Metals Corp

Fig. 4. Illustrative Example of a Rare Earth Processing Plant
Source: Getty Images – Pensana’s rare earth refinery at Saltend Chemicals Park. Image is illustrative only and is not the proposed CRML Romania refinery.

About Critical Metals Corp.

Critical Metals Corp (Nasdaq: CRML) is a leading mining development company focused on critical metals and minerals, and producing strategic products essential to electrification and next generation technologies for Europe and its western world partners. Its flagship Project, Tanbreez, is one of the world’s largest, rare earth deposits and is located in Southern Greenland. The deposit is expected to have access to key transportation outlets as the area features year-round direct shipping access via deep water fjords that lead directly to the North Atlantic Ocean.

Another key asset is the Wolfsberg Lithium Project located in Carinthia, 270 km south of Vienna, Austria. The Wolfsberg Lithium Project is the first fully permitted mine in Europe and is strategically located with access to established road and rail infrastructure and is expected to be the next major producer of key lithium products to support the European market. Wolfsberg is well positioned with offtake and downstream partners to become a unique and valuable asset in an expanding geostrategic critical metals portfolio.

With this strategic asset portfolio, Critical Metals Corp is positioned to become a reliable and sustainable supplier of critical minerals essential for defense applications, the clean energy transition, and next-generation technologies in the western world.

For more information, please visit https://www.criticalmetalscorp.com/.

Cautionary Note Regarding Forward Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements may include expectations of our business and the plans and objectives of management for future operations. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this news release, forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” “designed to” or other similar expressions that predict or indicate future events or trends or that are not statements of historical facts. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors discussed under the “Risk Factors” section in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are based on information available as of the date of this news release, and expectations, forecasts and assumptions as of that date, involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Critical Metals Corp.

Investor Relations: ir@criticalmetalscorp.com

Media: pr@criticalmetalscorp.com

Photos accompanying this announcement are available at 
https://www.globenewswire.com/NewsRoom/AttachmentNg/55640db4-cebc-4ebb-9622-7603bdbfc1e4
https://www.globenewswire.com/NewsRoom/AttachmentNg/de724907-0b33-41af-a7a4-5eca67228213
https://www.globenewswire.com/NewsRoom/AttachmentNg/f5411e9f-7a76-4171-bf20-453b0132e6f1
https://www.globenewswire.com/NewsRoom/AttachmentNg/5e1241cd-b80d-4b3f-9383-2e34adf8a4ff

16 SEPTEMBER 2026

NORTHERN VENTURE TRUST PLC

PUBLICATION OF AN OFFER DOCUMENT

Northern Venture Trust PLC (“the Company”) announces that, in conjunction with Northern 2 VCT PLC and Northern 3 VCT PLC (together with the Company known as “the Northern VCTs”), it has published an offer document (“the Offer Document”) in relation to offers of new ordinary shares for subscription in the 2026/27 tax year (“the Offers”). The Offers seek to raise £10 million for each of the Company, Northern 2 VCT PLC and Northern 3 VCT PLC, £30 million in aggregate.

The Offers will open to applications at 8.00am on 30 September 2026 and applications for new shares in the Company will be dealt with on a “first-come, first-served” basis. In recognition of the loyalty of the Northern VCT shareholders, existing shareholders on the register of members of any of the Northern VCTs as at 10 June 2026, along with their spouse or civil partner, whose applications for shares in any of the Northern VCTs are accepted, will benefit from a reduction of 0.5% in the offer costs applicable to their subscription. The Offers will remain open until 12 noon on 31 March 2027, unless fully subscribed at an earlier date and subject to the Directors’ right to close any of the Offers at any time. There will be a first allotment at the end of November 2026. To be allocated shares in the first allotment, funded valid applications must be received by 5.00pm on 23 November 2026.

Pursuant to an offer agreement between Mercia Fund Management Limited (“Mercia”), the Northern VCTs’ investment adviser/manager and promoter, the Northern VCTs and others, Mercia will, in respect of the services provided in connection to the Offers, receive up to a maximum of 5.5% (or 3.0% where no commission is payable) of the aggregate amounts of the subscription monies as received by the Northern VCTs pursuant to the Offers (the “Promoter’s Fee”). Pursuant to the offer agreement, Mercia agrees that it will pay all costs, charges, fees and expenses payable by the Northern VCTs or Mercia in connection with, or incidental to, the Offers and the admission of the ordinary shares of the Northern VCTs issued pursuant to the Offers.

Mercia, as the investment adviser of the Company, is a related party of the Company under UK Listing Rule 11.5.3R, and the arrangements to pay the Promoter’s Fee to Mercia (as they relate to each of the Northern VCTs) constitutes a relevant related party transaction of the Company of an adequate size under UK Listing Rule 11.5.4R for UK Listing Rule 8.2.1R(1) to (4) to apply. The board of the Company believes that the transaction is fair and reasonable as far as the shareholders of the Company are concerned and have been provided with written confirmation of this by Howard Kennedy Corporate Services LLP as sponsor to the Company.

The Offer Document, describing the key features of the Offers will be sent to registered shareholders in accordance with their communication preferences, as soon as possible.

A downloadable version of the Offer Document is available from: www.mercia.co.uk/vct-share-offers/. Additionally, a copy is available free of charge, from the Company’s registered office at Forward House, 17 High Street, Henley-in-Arden B95 5AA or by calling Mercia on 0330 223 1430.

Enquiries:

Sarah Williams / James Sly, Mercia Fund Management Limited – 0330 223 1430

Website: www.mercia.co.uk/vcts

Neither the contents of the Mercia Asset Management PLC website, nor the contents of any website accessible from hyperlinks on the Mercia Asset Management PLC website (or any other website), are incorporated into, or form part of, this announcement.

16 SEPTEMBER 2026

NORTHERN 2 VCT PLC

PUBLICATION OF AN OFFER DOCUMENT

Northern 2 VCT PLC (“the Company”) announces that, in conjunction with Northern Venture Trust PLC and Northern 3 VCT PLC (together with the Company known as “the Northern VCTs”), it has published an offer document (“the Offer Document”) in relation to offers of new ordinary shares for subscription in the 2026/27 tax year (“the Offers”). The Offers seek to raise £10 million for each of the Company, Northern Venture Trust PLC and Northern 3 VCT PLC, £30 million in aggregate.

The Offers will open to applications at 8.00am on 30 September 2026 and applications for new shares in the Company will be dealt with on a “first-come, first-served” basis. In recognition of the loyalty of the Northern VCT shareholders, existing shareholders on the register of members of any of the Northern VCTs as at 10 June 2026, along with their spouse or civil partner, whose applications for shares in any of the Northern VCTs are accepted, will benefit from a reduction of 0.5% in the offer costs applicable to their subscription. The Offers will remain open until 12 noon on 31 March 2027, unless fully subscribed at an earlier date and subject to the Directors’ right to close any of the Offers at any time. There will be a first allotment at the end of November 2026. To be allocated shares in the first allotment, funded valid applications must be received by 5.00pm on 23 November 2026.

Pursuant to an offer agreement between Mercia Fund Management Limited (“Mercia”), the Northern VCTs’ investment adviser/manager and promoter, the Northern VCTs and others, Mercia will, in respect of the services provided in connection to the Offers, receive up to a maximum of 5.5% (or 3.0% where no commission is payable) of the aggregate amounts of the subscription monies as received by the Northern VCTs pursuant to the Offers (the “Promoter’s Fee”). Pursuant to the offer agreement, Mercia agrees that it will pay all costs, charges, fees and expenses payable by the Northern VCTs or Mercia in connection with, or incidental to, the Offers and the admission of the ordinary shares of the Northern VCTs issued pursuant to the Offers.

Mercia, as the investment manager of the Company, is a related party of the Company under UK Listing Rule 11.5.3R, and the arrangements to pay the Promoter’s Fee to Mercia (as they relate to each of the Northern VCTs) constitutes a relevant related party transaction of the Company of an adequate size under UK Listing Rule 11.5.4R for UK Listing Rule 8.2.1R(1) to (4) to apply. The board of the Company believes that the transaction is fair and reasonable as far as the shareholders of the Company are concerned and have been provided with written confirmation of this by Howard Kennedy Corporate Services LLP as sponsor to the Company.

The Offer Document, describing the key features of the Offers will be sent to registered shareholders in accordance with their communication preferences, as soon as possible.

A downloadable version of the Offer Document is available from: www.mercia.co.uk/vct-share-offers/. Additionally, a copy is available free of charge, from the Company’s registered office at Forward House, 17 High Street, Henley-in-Arden B95 5AA or by calling Mercia on 0330 223 1430.

Enquiries:

Sarah Williams / James Sly, Mercia Fund Management Limited – 0330 223 1430

Website: www.mercia.co.uk/vcts

Neither the contents of the Mercia Asset Management PLC website, nor the contents of any website accessible from hyperlinks on the Mercia Asset Management PLC website (or any other website), are incorporated into, or form part of, this announcement.

16 SEPTEMBER 2026

NORTHERN 3 VCT PLC

PUBLICATION OF AN OFFER DOCUMENT

Northern 3 VCT PLC (“the Company”) announces that, in conjunction with Northern Venture Trust PLC and Northern 2 VCT PLC (together with the Company known as “the Northern VCTs”), it has published an offer document (“the Offer Document”) in relation to offers of new ordinary shares for subscription in the 2026/27 tax year (“the Offers”). The Offers seek to raise £10 million for each of the Company, Northern Venture Trust PLC and Northern 2 VCT PLC, £30 million in aggregate.

The Offers will open to applications at 8.00am on 30 September 2026 and applications for new shares in the Company will be dealt with on a “first-come, first-served” basis. In recognition of the loyalty of the Northern VCT shareholders, existing shareholders on the register of members of any of the Northern VCTs as at 10 June 2026, along with their spouse or civil partner, whose applications for shares in any of the Northern VCTs are accepted, will benefit from a reduction of 0.5% in the offer costs applicable to their subscription. The Offers will remain open until 12 noon on 31 March 2027, unless fully subscribed at an earlier date and subject to the Directors’ right to close any of the Offers at any time. There will be a first allotment at the end of November 2026. To be allocated shares in the first allotment, funded valid applications must be received by 5.00pm on 23 November 2026.

Pursuant to an offer agreement between Mercia Fund Management Limited (“Mercia”), the Northern VCTs’ investment adviser/manager and promoter, the Northern VCTs and others, Mercia will, in respect of the services provided in connection to the Offers, receive up to a maximum of 5.5% (or 3.0% where no commission is payable) of the aggregate amounts of the subscription monies as received by the Northern VCTs pursuant to the Offers (the “Promoter’s Fee”). Pursuant to the offer agreement, Mercia agrees that it will pay all costs, charges, fees and expenses payable by the Northern VCTs or Mercia in connection with, or incidental to, the Offers and the admission of the ordinary shares of the Northern VCTs issued pursuant to the Offers.

Mercia, as the investment manager of the Company, is a related party of the Company under UK Listing Rule 11.5.3R, and the arrangements to pay the Promoter’s Fee to Mercia (as they relate to each of the Northern VCTs) constitutes a relevant related party transaction of the Company of an adequate size under UK Listing Rule 11.5.4R for UK Listing Rule 8.2.1R(1) to (4) to apply. The board of the Company believes that the transaction is fair and reasonable as far as the shareholders of the Company are concerned and have been provided with written confirmation of this by Howard Kennedy Corporate Services LLP as sponsor to the Company.

The Offer Document, describing the key features of the Offers will be sent to registered shareholders in accordance with their communication preferences, as soon as possible.

A downloadable version of the Offer Document is available from: www.mercia.co.uk/vct-share-offers/. Additionally, a copy is available free of charge, from the Company’s registered office at Forward House, 17 High Street, Henley-in-Arden B95 5AA or by calling Mercia on 0330 223 1430.

Enquiries:

Sarah Williams / James Sly, Mercia Fund Management Limited – 0330 223 1430

Website: www.mercia.co.uk/vcts

Neither the contents of the Mercia Asset Management PLC website, nor the contents of any website accessible from hyperlinks on the Mercia Asset Management PLC website (or any other website), are incorporated into, or form part of, this announcement.

Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers

VANCOUVER, British Columbia, Sept. 16, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or the “Company“), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announces plans to initiate a Health Canada-authorized Phase 3 clinical trial evaluating MDMA (3,4-methylenedioxymethamphetamine)-assisted therapy for individuals with post-traumatic stress disorder (“PTSD“). The trial is expected to begin in 2027.

The Phase 3 clinical trial is intended to enroll up to 100 participants across multiple sites in Canada, with enrollment focused on veterans and current or former frontline workers, including military, police, paramedics, firefighters and healthcare workers. Participants will receive the Company’s synthetic MDMA HCl, supplied in two dosage formats, during two supervised sessions combining MDMA and psychotherapy, spaced several weeks apart, with follow-up evaluations after the final session. The primary efficacy endpoint will be change in the Clinician-Administered PTSD Scale (CAPS-5), the standard clinician-rated instrument for assessing PTSD severity.

“On the heels of announcing our Phase 2 trial of natural psilocybin for the treatment of major depressive disorder, we are preparing to advance our synthetic MDMA into an approved Phase 3 trial in PTSD, with the goal of submitting both products for registration,” said Dane Stevens, Optimi’s Chief Executive Officer and Co-Founder. “PTSD and major depressive disorder are large, underserved markets. Millions of patients around the globe continue to struggle despite existing treatments, and veterans and frontline workers carry a disproportionate share of that burden. Psychedelic-assisted therapies have shown promise in helping patients find relief.”

Post-traumatic stress disorder is a mental health condition that can develop after experiencing or witnessing a terrifying, life-threatening, or deeply traumatic event. People with PTSD typically experience severe, persistent distress that significantly disrupts daily functioning. Worldwide, an estimated 70% of people will experience a traumatic event during their lifetime, with an estimated 3.9% of the global population developing the disorder. Many people with PTSD see limited benefit from first-line treatments such as trauma-focused psychotherapy and antidepressants, leaving a pressing need for new therapeutics.

The safety and efficacy of MDMA-assisted therapy to treat PTSD are still under investigation, and none of Optimi’s MDMA drug products have received market authorization from Health Canada. Clinics in Australia have been prescribing MDMA manufactured by Optimi since October 2024.

About Optimi Health Corp.

Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.

For more information, please visit optimi.net.

For more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
(778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca

Investor Relations Contact:
CORE IR
ir@optimi.net

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including statements regarding the proposed clinical trial, the availability and enrolment of patients in the trial, the utilization of the data derived from the trial, and the ability to conduct evaluations as part of the trial, the potential benefits of MDMA, the Company’s ability to manufacture and ship products from its Canadian facility, and the Company’s positioning in the regulated psychedelic medicine market. Forward-looking statements and forward-looking information are often identified by words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “estimates,” “may,” “will,” “would,” “could,” or similar expressions. Forward-looking statements and forward-looking information are based on several assumptions and are subject to a number of known and unknown risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include those described under “Risk Factors” in the Company’s registration statement on Form F-1, as amended, and other filings with the U.S. Securities and Exchange Commission made from time to time which are available at www.sec.gov and on SEDAR+ at www.sedarplus.ca and in the Company’s continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. These forward-looking statements reflect current expectations of management regarding future events and speak only as of the date of this press release. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

Notice of Annual General Meeting 2026

ANNOUNCEMENT NO. 314
16 September 2026

Notice of Annual General Meeting
Notice is hereby given of the Annual General Meeting, which will be held on Thursday 8 October 2026 at 5.30 p.m.

The general meeting will be held at Nordsjællands KonferenceCenter, Gydevang 39-41, 3450 Allerød.

Additional info
Phillip Massie Price, CFO
Telefon (+45) 81 10 06 80

About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies. ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.

Attachment

Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies 

U.S. expansion is funded by a $2.3 million NIH grant to MAIA to support third-line treatment evaluation

CHICAGO, Sept. 16, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the first U.S. patient has been dosed in its Phase 2 THIO-101 trial expansion evaluating its telomere-targeting lead candidate, ateganosine, in third-line non-small cell lung cancer (NSCLC). The U.S. Phase 2 expansion is funded by a $2.3 million grant from the National Institutes of Health (NIH) to support third-line treatment evaluation and MAIA has activated 3 sites in the U.S.

MAIA holds FDA Fast Track designation for ateganosine, a dual mechanism therapy designed to break down telomere structure and function in cancer cells while inducing immune activation. Prior data from THIO-101 Parts A and B show overall survival (OS) beyond 24 months in eight patients receiving ateganosine sequenced with a checkpoint inhibitor.

“We have worked diligently to advance ateganosine into the U.S. market, and dosing the first patient in the United States represents a major milestone for our ongoing Phase 2 clinical trial,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “Our collaborations with some of the nation’s top institutions and foremost oncologists further strengthen the trial as we evaluate ateganosine for patients in advanced stages of this exceedingly hard-to-treat disease. We believe the data generated through the THIO-101 program may also support a potential pathway toward FDA accelerated approval. With patients now enrolled across four continents, the study has evolved into a truly global effort focused on addressing a critical unmet need in cancer care.”

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101 Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.